Quantcast

EndoChoice Announces Patient Resource Website Launch In Conjunction with Colorectal Cancer Awareness Month

March 26, 2014

FuseColonoscopy.org serves as key portal to dispel fears and concerns about colonoscopy

ATLANTA, March 26, 2014 /PRNewswire/ — EndoChoice Inc.(® )maker of the Fuse(TM) Full Spectrum Endoscopy(TM) system that allows doctors to see more of the GI tract than ever before today announced the launch of FuseColonoscopy.org to provide patients with the latest information on colorectal cancer screening. The release is planned to coincide with National Colorectal Cancer Awareness Month that EndoChoice is committed to support as a key initiative in helping reduce the incidence and mortality of colorectal cancer.

This easy to navigate website is a great resource for patients who want to learn more about colorectal cancer, the colorectal cancer screening process, and where to find doctors using Fuse to provide the most comprehensive detection technology available today. Visitors to the site will be able to access important tools, videos and links to remove some of the mystery and uncertainty about important endoscopy procedures such as colonoscopy.

“Although disease awareness efforts around colorectal cancer have grown tremendously, colon cancer remains a deadly force, taking over 50,000 lives in the US each year,” said, Mark Gilreath, Founder and CEO of EndoChoice, Inc. “We are committed to advancing the technology and research that will improve screening and diagnostic procedures, as well as expanding educational programs that underscore the importance of colorectal cancer screening.”

EndoChoice also announced it has partnered with AliveAndKickn, a patient advocacy organization, founded by three-time cancer survivor and patient advocate, David Dubin. EndoChoice will support Mr. Dubin and his organization for AliveAndKickn’s “Blue Genes Bash” event celebrating life and raising funds for colon cancer awareness and research.

“Just last week a new study was released in The Lancet Oncology that demonstrated Fuse found more pre-cancerous lesions than standard, forward-viewing colonoscopes,” added Gilreath. “It is important for people to talk with their doctors about colorectal cancer and get educated about the options available to them. This disease can be defeated if you get screened at the appropriate times and ask your doctor to use the most advanced imaging technology available.”

About EndoChoice
Based in Atlanta GA, EndoChoice(®) is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal (GI) diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy(TM) System (Fuse(TM)). The Fuse System is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract for diagnosis and treatment. The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from traditional endoscopes. In a recent clinical study Fuse found 76% more polyps than traditional colonoscopes. 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com. Follow Fuse(TM) colonoscopy on Twitter #fusecolonoscopy.

For further information contact:
Fern Lazar/Martyna Gawrych
Lazar Partners Ltd.
flazar@lazarpartners.com
mgawrych@lazarpartners.com
212-867-1762

SOURCE EndoChoice, Inc.


Source: PR Newswire



comments powered by Disqus